Livestock drug company Zoetis (NYSE:ZTS) is on the end of a positive market reaction as investors troop in following its Q3 result. Shares of the pet medicine and vaccine maker gained nearly 5% in Thursday’s afternoon trading session.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Notably, the company, earlier on Thursday, reported Q3 FY2023 EPS of $1.36, in line with Wall Street estimates. Sales increased by 7% year-over-year, with revenue hitting $2.2 billion. This beat analysts’ expectations by $30 million. For reference, analysts were expecting $2.17 billion in revenue.
According to the company, an 11% increase in demand for companion animal products, especially for dogs and cats, contributed significantly to its Q3 revenue.
In addition to the Q3 results, the company adjusted its full-year forecast to reflect the impact of foreign exchange rates. Importantly, management now expects revenue for the full year 2023 to be in the range of $8.475B to $8.55B.
Is Zoetis a Buy or Sell?
With three Buy recommendations, ZTS commands a Strong Buy consensus rating on TipRanks. The average ZTS price target of $201.67 implies a 26.44% upside potential from current levels. Meanwhile, ZTS stock has gained 9.48% this year, with numerous declines in recent months.
